title: Moxalactam versus clindamycin plus tobramycin for the treatment of puerperal infections.
abstract: Sixty women with the diagnosis of puerperal endometritis were randomized to receive either moxalactam (n = 29) or the combination of clindamycin and tobramycin (n = 31) as therapy for their infection. Endometrial bacteriology consisted of mixed flora, both aerobic and anaerobic gram-positive and gram-negative organisms. Clinical cure was achieved in 27 (93%) of the moxalactam-treated patients and 28 (90%) of those given combination therapy. The two failures of moxalactam therapy were associated with enterococcal infection. Failures of clindamycin/tobramycin therapy were due to enterococcal infection, abscess formation, and moderately severe diarrhea. This study indicates that moxalactam is as effective and safe as the combination of clindamycin/tobramycin for the treatment of postpartum endometritis.
authors.forename: J G
authors.initials: JG
authors.lastname: Pastorek
authors.forename: S
authors.initials: S
authors.lastname: Faro
authors.forename: K E
authors.initials: KE
authors.lastname: Aldridge
authors.forename: S K
authors.initials: SK
authors.lastname: Nicaud
mesh_terms: D002981:Clindamycin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D004716:Endometritis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D009070:Moxalactam / Q000627:therapeutic use*; D011247:Pregnancy; D011446:Prospective Studies; D011645:Puerperal Infection / Q000188:drug therapy*; D011897:Random Allocation; D014031:Tobramycin / Q000627:therapeutic use*
chemical_list: D002981:Clindamycin; D009070:Moxalactam; D014031:Tobramycin